AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$KURA

DOYLE THOMAS JAMES sold $48K of KURA

DOYLE THOMAS JAMES (SVP, Finance & Accounting) sold 4,607 shares of Kura Oncology, Inc. (KURA) at $10.50 on 2026-09-28.

Original reporting
SEC EDGAR · DOYLE THOMAS JAMES
Published Sep 29, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 10:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KURA
Bearish
medium confidence
Mentioned
$KURA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURABearishLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

Timing

post-market today

Relevance 3/10Novelty 3/10Timing: post-market today

Background

Form 4 filing reports an insider transaction for Kura Oncology.

Company-level read

Ticker impact

$KURABearishMedium confidence
Context

Insider sold 4,607 shares for $48,360.60, reducing holdings to 142,428 shares.

Expected impact

likely modest pressure as market prices in the insider sell.

Evidence & confidence

Small transaction size and lack of accompanying news suggest limited impact.

Market effects

Sector

minimal effect on biotech sector

Regional

none

Global

none

Key entities

  • Insider
    Doyle Thomas James

    SVP, Finance & Accounting at Kura Oncology

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

OCT 13
$KURAMedAI 8/10

Some rats regained normal blood sugar for a month after an experimental diabetes treatment stopped

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

stocktitan.net2 min
SEP 29
$KURAMedAI 8/10

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Caspian Therapeutics and Kura Oncology presented preclinical data on KO-7246, a menin inhibitor, showing potential for diabetes treatment. KO-7246 regenerated β-cell mass and controlled glycemic levels in Type 1 and Type 2 diabetes models. Caspian aims to develop KO-7246 as a best-in-class therapy, with an investor event scheduled for October 13, 2026.

finance.yahoo.com3 min
SEP 9
$KURAMed

KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil

Kura Oncology (KURA) launched Caspian Therapeutics, a spin-off focused on menin inhibition therapies for diabetes and cardiometabolic diseases. Kura retains 50% ownership. The company's P/S ratio is 14.3x, above its historical median of 10.6x, reflecting growth expectations despite unprofitability. Insider activity shows net selling, while guru investors have mixed positions.

gurufocus.com2 min